Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rayson

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
International Journal of Surgery Case Reports|October 27, 2018
Report of metastatic ileal neuroendocrine tumor to the submandibular glandDavid Forner, Peter Cho, Martin Bullock, et al.
Clinical Breast Cancer|March 23, 2011
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control studyDaniel Rayson, Jennifer Isabelle Payne, Mohamed Abdolell, et al.
Therapeutic Advances in Medical Oncology|January 17, 2022
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the linesChristine Simmons, Daniel Rayson, Anil Abraham Joy, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN StudyDaniel Rayson, Jonathan Bertin, Maxim Lemelin, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
Annals of Surgical Oncology|November 5, 2014
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert GroupSimron Singh, Chris Dey, Hagen Kennecke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesMaureen E Trudeau, Mark J Clemons, Louise Provencher, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsRoger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumorsHenry C Pitot, Joel M Reid, Jeff A Sloan, et al.
Cancer Treatment Reviews|February 28, 2012
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsJohn R Mackey, Robert S Kerbel, Karen A Gelmon, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
International Journal of Surgery Case Reports|October 27, 2018
Report of metastatic ileal neuroendocrine tumor to the submandibular glandDavid Forner, Peter Cho, Martin Bullock, et al.
Clinical Breast Cancer|March 23, 2011
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control studyDaniel Rayson, Jennifer Isabelle Payne, Mohamed Abdolell, et al.
Therapeutic Advances in Medical Oncology|January 17, 2022
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the linesChristine Simmons, Daniel Rayson, Anil Abraham Joy, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN StudyDaniel Rayson, Jonathan Bertin, Maxim Lemelin, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
Annals of Surgical Oncology|November 5, 2014
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert GroupSimron Singh, Chris Dey, Hagen Kennecke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesMaureen E Trudeau, Mark J Clemons, Louise Provencher, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsRoger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumorsHenry C Pitot, Joel M Reid, Jeff A Sloan, et al.
Cancer Treatment Reviews|February 28, 2012
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsJohn R Mackey, Robert S Kerbel, Karen A Gelmon, et al.
Pageof 9